Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.
The role of chemokines in the pathogenesis of lung cancer has been increasingly appreciated. Monocyte chemoattractant protein-1 (MCP-1, also known as CCL2) is secreted from tumor cells and associated tumor stromal cells. The blockade of CCL2, as mediated by neutralizing antibodies, was shown to reduce tumorigenesis in several solid tumors, but the role of CCL2 in lung cancer remains controversial, with evidence of both protumorigenic and antitumorigenic effects. We evaluated the effects and mechanisms of CCL2 blockade in several animal models of non-small-cell lung cancer (NSCLC). Anti-murine-CCL2 monoclonal antibodies were administered in syngeneic flank and orthotopic models of NSCLC. CCL2 blockade significantly slowed the growth of primary tumors in all models studied, and inhibited lung metastases in a model of spontaneous lung metastases of NSCLC. In contrast to expectations, no significant effect of treatment was evident in the number of tumor-associated macrophages recruited into the tumor after CCL2 blockade. However, a change occurred in the polarization of tumor-associated macrophages to a more antitumor phenotype after CCL2 blockade. This was associated with the activation of cytotoxic CD8(+) T lymphocytes (CTLs). The antitumor effects of CCL2 blockade were completely lost in CB-17 severe combined immunodeficient mice or after CD8 T-cell depletion. Our data from NSCLC models show that CCL2 blockade can inhibit the tumor growth of primary and metastatic disease. The mechanisms of CCL2 blockade include an alteration of the tumor macrophage phenotype and the activation of CTLs. Our work supports further evaluation of CCL2 blockade in thoracic malignancies.
Fridlender
Zvi G
ZG
Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, USA. fridlender@hadassah.org.il
Kapoor
Veena
V
Buchlis
George
G
Cheng
Guanjun
G
Sun
Jing
J
Wang
Liang-Chuan S
LC
Singhal
Sunil
S
Snyder
Linda A
LA
Albelda
Steven M
SM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000473:pathology / Q000556:secondary / Q000628:therapy; D045744:Cell Line, Tumor; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors* / Q000276:immunology; D005260:Female; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D008213:Lymphocyte Activation; D008212:Lymphocyte Depletion; D008264:Macrophages / Q000276:immunology*; D008654:Mesothelioma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D051379:Mice; D057507:Mice, 129 Strain; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D010641:Phenotype; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000911:Antibodies, Monoclonal; C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2
Hum Antibodies. 2007;16(3-4):117-25
18334747
J Immunol. 2005 Oct 1;175(7):4583-92
16177103
Cancer Lett. 2007 Jul 8;252(1):86-92
17257744
Cancer Immunol Immunother. 2000 May;49(2):63-70
10823415
Neoplasia. 2006 Jul;8(7):578-86
16867220
Clin Cancer Res. 2005 Sep 15;11(18):6713-21
16166452
J Biol Chem. 2009 Dec 4;284(49):34342-54
19833726
J Exp Med. 1997 Jan 6;185(1):99-109
8996246
J Lab Clin Med. 2002 Nov;140(5):320-8
12434133
Immunol Lett. 2007 Oct 31;113(1):19-28
17868906
Cancer Res. 2007 Oct 1;67(19):9417-24
17909051
J Cell Biochem. 2008 Aug 1;104(5):1587-97
18646053
Nat Rev Immunol. 2005 Dec;5(12):953-64
16322748
Cytokine. 2008 Oct;44(1):191-200
18790652
Neoplasia. 2007 Jul;9(7):556-62
17710158
Hum Cell. 1999 Dec;12(4):197-204
10834106
Semin Cancer Biol. 2004 Jun;14(3):149-54
15246049
Cancer Res. 1997 Nov 1;57(21):4849-54
9354448
J Immunol. 2001 Jun 1;166(11):6483-90
11359798
Blood. 2000 Jul 1;96(1):34-40
10891427
Cancer Res. 2005 Dec 15;65(24):11752-61
16357188
Int J Cancer. 1997 Apr 10;71(2):257-66
9139852
Clin Cancer Res. 2006 Jan 1;12(1):214-22
16397045
J Clin Invest. 2006 Aug;116(8):2132-2141
16862213
Immunol Rev. 2008 Apr;222:155-61
18364000
J Immunol. 2003 Nov 15;171(10):5051-63
14607902
Cancer Immunol Immunother. 1998 Oct;47(2):72-80
9769115
Carcinogenesis. 2005 Mar;26(3):513-23
15358632
Trends Immunol. 2002 Nov;23(11):549-55
12401408
J Immunol. 2007 Sep 1;179(5):3332-41
17709550
J Immunol. 2008 Mar 1;180(5):2886-93
18292510
Growth Factors. 1994;11(1):29-44
7833058
Annu Rev Immunol. 2007;25:267-96
17134371
Cancer Res. 2005 Apr 15;65(8):3437-46
15833879
Clin Cancer Res. 2006 Aug 15;12(16):4794-803
16914564
Cancer Res. 2005 Sep 15;65(18):8379-87
16166316
J Leukoc Biol. 2008 Sep;84(3):679-88
18566103
Cancer Res. 2010 Jan 1;70(1):109-18
20028856
Blood. 2005 Nov 1;106(9):3322-30
16037386
J Exp Med. 1998 Feb 16;187(4):601-8
9463410
J Cancer Res Clin Oncol. 2005 Jul;131(7):453-8
15883814
Cancer Immunol Immunother. 2008 Jan;57(1):123-31
17522861
Cancer Sci. 2009 Mar;100(3):419-28
19154405
Neoplasia. 2009 Mar;11(3):228-36
19242604
J Exp Med. 2008 Jun 9;205(6):1261-8
18490490
Cancer Metastasis Rev. 2007 Dec;26(3-4):737-47
17846863
Cancer Res. 2009 Feb 15;69(4):1685-92
19176388
Cancer Res. 1996 Jan 1;56(1):21-6
8548765
Cancer Res. 2000 Dec 15;60(24):7002-7
11156403